MX362610B - Usos de bremelanotida en terapia para la disfunción sexual femenina. - Google Patents

Usos de bremelanotida en terapia para la disfunción sexual femenina.

Info

Publication number
MX362610B
MX362610B MX2015005486A MX2015005486A MX362610B MX 362610 B MX362610 B MX 362610B MX 2015005486 A MX2015005486 A MX 2015005486A MX 2015005486 A MX2015005486 A MX 2015005486A MX 362610 B MX362610 B MX 362610B
Authority
MX
Mexico
Prior art keywords
bremelanotide
sexual dysfunction
female sexual
therapy
composition
Prior art date
Application number
MX2015005486A
Other languages
English (en)
Spanish (es)
Other versions
MX2015005486A (es
Inventor
Spana Carls
Jordan Robert
D Edelson Jeffrey
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX362610(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of MX2015005486A publication Critical patent/MX2015005486A/es
Publication of MX362610B publication Critical patent/MX362610B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
MX2015005486A 2012-11-05 2013-11-05 Usos de bremelanotida en terapia para la disfunción sexual femenina. MX362610B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (2)

Publication Number Publication Date
MX2015005486A MX2015005486A (es) 2015-11-13
MX362610B true MX362610B (es) 2019-01-28

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005486A MX362610B (es) 2012-11-05 2013-11-05 Usos de bremelanotida en terapia para la disfunción sexual femenina.

Country Status (23)

Country Link
US (7) US9352013B2 (enExample)
EP (1) EP2916856B2 (enExample)
JP (1) JP6567971B2 (enExample)
KR (1) KR102253526B1 (enExample)
CN (2) CN117860866A (enExample)
AU (1) AU2013337341B2 (enExample)
BR (1) BR112015009936A8 (enExample)
DK (1) DK2916856T4 (enExample)
EA (1) EA032959B9 (enExample)
ES (1) ES2701444T5 (enExample)
FI (1) FI2916856T4 (enExample)
GE (2) GEP20196947B (enExample)
HK (1) HK1211227A1 (enExample)
IL (1) IL238276B (enExample)
MX (1) MX362610B (enExample)
MY (1) MY179755A (enExample)
NZ (1) NZ707246A (enExample)
PH (1) PH12015500915B1 (enExample)
PL (1) PL2916856T5 (enExample)
SG (1) SG11201502949QA (enExample)
UA (1) UA118656C2 (enExample)
WO (1) WO2014071339A2 (enExample)
ZA (1) ZA201503128B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) * 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1289587B1 (en) * 2000-05-31 2005-08-03 Novo Nordisk A/S A disposable double pointed injection needle
EP1441750A4 (en) 2001-07-11 2006-10-18 Palatin Technologies Inc LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
EP1819380B1 (en) * 2004-12-09 2018-04-04 West Pharmaceutical Services, Inc. Automatic injection and retraction syringe
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
AU2009257631B2 (en) * 2008-06-09 2014-07-24 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
AU2011242602B2 (en) * 2010-04-21 2015-06-18 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents

Also Published As

Publication number Publication date
KR102253526B1 (ko) 2021-05-18
JP6567971B2 (ja) 2019-08-28
AU2013337341A1 (en) 2015-05-07
BR112015009936A2 (pt) 2017-07-11
AU2013337341B2 (en) 2018-02-22
US9352013B2 (en) 2016-05-31
GEP20196947B (en) 2019-02-11
US20220362328A1 (en) 2022-11-17
US20140378392A1 (en) 2014-12-25
IL238276B (en) 2020-04-30
DK2916856T4 (da) 2024-01-22
PL2916856T3 (pl) 2019-02-28
MY179755A (en) 2020-11-12
WO2014071339A2 (en) 2014-05-08
US20210060120A1 (en) 2021-03-04
US10286034B2 (en) 2019-05-14
JP2016503406A (ja) 2016-02-04
DK2916856T3 (en) 2019-01-14
PH12015500915A1 (en) 2015-06-29
CN104755094A (zh) 2015-07-01
EA032959B1 (ru) 2019-08-30
US20240335502A1 (en) 2024-10-10
WO2014071339A3 (en) 2014-06-12
CN117860866A (zh) 2024-04-12
KR20150081345A (ko) 2015-07-13
US9700592B2 (en) 2017-07-11
EA201590760A1 (ru) 2015-10-30
EP2916856A4 (en) 2016-06-22
US20150231196A1 (en) 2015-08-20
US20180085425A1 (en) 2018-03-29
IL238276A0 (en) 2015-06-30
EA032959B9 (ru) 2019-11-27
PL2916856T5 (pl) 2024-01-29
EP2916856B1 (en) 2018-09-19
ZA201503128B (en) 2016-11-30
UA118656C2 (uk) 2019-02-25
SG11201502949QA (en) 2015-06-29
US20190216888A1 (en) 2019-07-18
EP2916856A2 (en) 2015-09-16
BR112015009936A8 (pt) 2019-09-17
HK1211227A1 (en) 2016-05-20
FI2916856T4 (fi) 2024-01-15
GEAP201813826A (en) 2018-10-25
ES2701444T3 (es) 2019-02-22
PH12015500915B1 (en) 2015-06-29
MX2015005486A (es) 2015-11-13
CA2890081A1 (en) 2014-05-08
ES2701444T5 (es) 2024-05-21
NZ707246A (en) 2019-03-29
EP2916856B2 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
MX2015013355A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
EA201400767A1 (ru) Подкожное терапевтическое применение ингибитора dpp-4
CR11724A (es) Agente para tratar enfermedades
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
MX352950B (es) Metodo para tratar condiciones neurologicas con glicosidos cardiacos.
MX2019007779A (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).
MX379066B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior.
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
CO6592015A2 (es) Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal
MX387113B (es) Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.
MX377897B (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
MX356808B (es) Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
MX362610B (es) Usos de bremelanotida en terapia para la disfunción sexual femenina.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
ZA202100604B (en) Methods to reduce complications of intra-articular steroid
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca

Legal Events

Date Code Title Description
FG Grant or registration